Development of cell-active BRD4-D1 selective inhibitors to decode the role of BET proteins in LPS-mediated liver inflammation

The endogenously expressed BET proteins (BRD2, BRD3, BRD4) are upstream clinical targets for anti-inflammatory treatments, where inhibition of the tandem bromodomains (D1 and D2) have proven efficacious in vitro and in vivo towards NF-κB-mediated inflammation. Despite their efficacy, dose-limiting toxicities associated with BET inhibition have limited clinical progression. One strategy to circumvent these dose-limiting toxicities has included domain- or protein-selective inhibition of the BET bromodomains. Based on previously reported 1,2,4-substituted imidazole scaffolds, we characterize and report on next-generation BRD4-D1 selective inhibitors, 39 and 41. Compound 39 is both highly potent and selective towards BRD4-D1 (K_i = 2.9 ± 1.0 nM, >1700-fold over BRD2-D1 via fluorescence anisotropy) over Other BET bromodomains in addition to being cell-active at nanomolar concentrations. We also characterized 39's solubility and cellular activity in addition to its off-target hERG liability (a common cardiovascular risk for drug candidates). An acetylated analogue, 41, had an 80-fold reduced hERG affinity compared to previous BRD4-D1 selective compounds. In the context of liver inflammation, we screened 39 against an LPS-mediated cellular model of liver inflammation. Upon treatment with 39, pro-inflammatory chemokines CXCL1 and CCL2 transcripts were significantly downregulated compared to the control; however, BRD4-D1 selective inhibition remained insufficient to reproduce the anti-inflammatory activity of pan-BET treatment. On a mechanistic level, these data highlight that more than one bromodomain within the BET family may be contributing to CXCL1 and CCL2 expression, where multi-domain inhibition or Other therapeutic modalities may be needed in these contexts to achieve sufficient anti-inflammatory effects.

Anti-inflammatory; Bromodomain; Cell-active; Epigenetics; Liver disease.